Cynvenio Biosystems Inc, Westlake Village, Calif, and Color, Burlingame, Calif, have partnered to offer the Color test, a hereditary cancer panel test. The test analyzes 30 genes, including BRCA1 and BRCA2, with Cynvenio’s ClearID breast cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations related to breast cancer.
The combined Color and ClearID tests aim to deliver a comprehensive approach to assessing hereditary breast cancer risk and monitoring patients at risk of disease. Mutations in the BRCA1 and BRCA2 genes are known risk factors for breast cancer.
The Color test also includes other genes associated with increased risk for the most common hereditary cancers, including colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers. The Color test includes access to board-certified genetic counseling for both clients and healthcare providers.
Cynvenio’s ClearID breast cancer test analyzes DNA from multiple sources in the bloodstream, including circulating tumor cells (CTCs), plasma or cell-free DNA (cfDNA), and germline DNA. The ClearID test was designed for patients undergoing treatment for advanced breast cancer and those requiring follow-up testing at regular intervals after completion of therapy. The test is powered by Cynvenio’s 27-gene NGS panel, which also provides an option to test protein biomarkers, including the antigen receptor splice variant 7 (AR-V7) and programmed cell death ligand 1 (PD-L1), without resampling the patient. Test results are summarized in a clear, actionable report for the physician.
André de Fusco, Cynvenio.
“Even well into therapy, too many patients do not seek BRCA testing because of concerns over cost or other reasons, which is unfortunate because BRCA status is important for evaluating treatment strategies,” says André de Fusco, CEO of Cynvenio. “With this new combined offering, we have demolished the cost barrier and integrated the biology, which will expand the availability of BRCA and hereditary cancer testing to more people who could benefit from it.”
Othman Laraki, Color.
Othman Laraki, cofounder and CEO of Color, adds, “Empowering people and their doctors to make more informed health decisions, the Color test has broadened the accessibility of DNA testing for hereditary cancers in an affordable, reliable, and convenient way. We are thrilled to partner with Cynvenio to make it more convenient for clinicians to receive a comprehensive report about a patient’s health status and risk factors.”
